Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday. Continue Reading
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test
